Tag: STEMI

1. There is no significant difference in 30-day all-cause mortality between radial and femoral access for percutaneous coronary intervention (PCI) following ST-segment elevation myocardial infarction (STEMI). Evidence Rating Level: 1 (Excellent) Primary percutaneous coronary intervention (PCI) is the standard of care for achieving reperfusion in patients with ST-segment elevation myocardial infarction (STEMI)....
1. There is no significant difference in 30-day all-cause mortality between radial and femoral access for percutaneous coronary intervention (PCI) following ST-segment elevation myocardial infarction (STEMI). Evidence Rating Level: 1 (Excellent) Primary percutaneous coronary intervention (PCI) is the standard of care for achieving reperfusion in patients with ST-segment elevation myocardial infarction (STEMI)....
Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial 1. Immune-related adverse events are associated with a longer recurrence-free survival in patients with stage III melanoma treated with pembrolizumab. Evidence Rating Level:...
1. In patients with STEMI and multivessel coronary artery disease, those randomized to the complete revascularization group experienced lower rates of cardiovascular death or myocardial infarction (MI) at 3 years compared to patients who were randomized to the culprit-lesion-only percutaneous coronary intervention group. 2. Both groups experienced similar rates of...
1. Patients with obesity undergoing percutaneous coronary intervention are typically younger with more cardiovascular risk factors, but may be less likely to experience procedural complications, short-term and long-term adverse outcomes, with the exception of patients considered extremely obese Evidence Rating Level: 2 (Good) It has been well established that obesity is...
1. In patients with STEMI and multivessel coronary artery disease, those randomized to the complete revascularization group experienced lower rates of cardiovascular death or myocardial infarction (MI) at 3 years compared to patients who were randomized to the culprit-lesion-only percutaneous coronary intervention group. 2. Both groups experienced similar rates of...
The risk of adverse cardiovascular outcomes in patients hospitalized with acute coronary syndrome (ACS) is highest in elderly patients. Although recent clinical trials have shown that high-intensity statin therapy significantly reduces adverse cardiovascular events for patients with established coronary heart disease, its use in elderly individuals remains controversial. As...
1. In this retrospective analysis of patients 75-years or older with ST-elevation myocardial infarction (STEMI) and cardiogenic shock, use of percutaneous coronary intervention (PCI) was associated with lower in-hospital mortality. 2. The use of PCI for older patients with STEMI and shock increased during the study period. Evidence Rating Level: 2...
1. In this randomized controlled trial, low-dose intracoronary alteplase given early during primary percutaneous coronary intervention (PCI) for acute ST-Elevation Myocardial Infarction (STEMI) did not reduce microvascular obstruction. 2. Health related quality of life was not improved with low-dose intracoronary alteplase. Evidence Rating Level: 1 (Excellent) Study Rundown: Acute coronary thrombosis causes...
Ischemic heart disease, the most common cause of morbidity and mortality worldwide, has many modifiable and non-modifiable risk factors, including several external factors. This retrospective observational study aimed to investigate circadian rhythms, major sports events, and national holidays as potential triggers of myocardial infarction. Investigators reviewed 283,014 cases of...